Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Ejhaem|May 19, 2023
A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)Mayur Narkhede, Nancy L Bartlett, Sami Ibrahimi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2006
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphomaRoberto Rodriguez, Auayporn Nademanee, Nora Ruel, et al.
Leukemia & Lymphoma|June 25, 2011
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease controlJasmine Zain, Joycelynne M Palmer, Maria Delioukina, et al.
Leukemia & Lymphoma|February 20, 2016
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium studyMark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
Cancer|June 6, 2014
Factors associated with high burden in caregivers of older adults with cancerTina Hsu, Matthew Loscalzo, Rupal Ramani, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2024
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin LymphomaMatthew Mei, Ni-Chun Tsai, Joycelynne Palmer, et al.
Leukemia & Lymphoma|March 8, 2017
Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trialsAndrei Shustov, Bertrand Coiffier, Steven Horwitz, et al.
Haematologica|January 18, 2015
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphomaRobert Chen, Paul Frankel, Leslie Popplewell, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2012
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL studyFrancine Foss, Steven M Horwitz, Bertrand Coiffier, et al.
Blood|October 24, 2002
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effectLaurence J N Cooper, Max S Topp, Lisa Marie Serrano, et al.
Pageof 7